Related Experiment Videos
CD52 expression in mantle cell lymphoma
Adam J Bass1, Jerald Gong, Ramona Nelson
1Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA. ajb14@duke.edu
Leukemia & Lymphoma
|May 10, 2002
Summary
Mantle cell lymphoma is challenging to treat. However, tumor cells in mantle cell lymphoma express the CD52 antigen, suggesting that CAMPATH-1H therapy may be effective for these patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma with limited treatment options.
- CAMPATH-1H (alemtuzumab) is a monoclonal antibody effective in other B-cell malignancies like chronic lymphocytic leukemia.
Purpose of the Study:
- To investigate the expression of the CD52 antigen in mantle cell lymphoma tumor samples.
- To evaluate the potential of CAMPATH-1H as a therapeutic agent for mantle cell lymphoma.
Main Methods:
- Analysis of mantle cell lymphoma patient tumor samples.
- Immunohistochemical detection of CD52 antigen expression.
Main Results:
- Mantle cell lymphoma tumor cells were found to express the CD52 antigen.
- This expression suggests susceptibility to CAMPATH-1H therapy.
Conclusions:
- The CD52 antigen is present on mantle cell lymphoma cells.
- CAMPATH-1H warrants further investigation as a potential treatment for mantle cell lymphoma.